First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation

被引：7
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, Dept Chem, San Diego, CA 92121 USA
[2] Bharath Univ, Chennai 600126, Tamil Nadu, India
来源：
CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 03期
关键词：
Non-small cell lung cancer; KRAS mutation; guanosine triphosphate; guanosine diphosphate; adagrasib; sotorasib; RESISTANCE; RAS;
D O I：
10.2174/0929867330666230330122000
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRAS(G12C). It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRAS(G12C )mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.
引用
收藏
页码：266 / 272
页数：7
相关论文
共 50 条
  • [1] Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
    Jaenne, Pasi A.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Heist, Rebecca S.
    Ou, Sai-Hong I.
    Pacheco, Jose M.
    Johnson, Melissa L.
    Sabari, Joshua K.
    Leventakos, Konstantinos
    Yau, Edwin
    Bazhenova, Lyudmila
    Negrao, Marcelo V.
    Pennell, Nathan A.
    Zhang, Jun
    Anderes, Kenna
    Der-Torossian, Hirak
    Kheoh, Thian
    Velastegui, Karen
    Yan, Xiaohong
    Christensen, James G.
    Chao, Richard C.
    Spira, Alexander I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02): : 120 - 131
  • [2] Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
    Bekaii-Saab, Tanios S.
    Yaeger, Rona
    Spira, Alexander I.
    Pelster, Meredith S.
    Sabari, Joshua K.
    Hafez, Navid
    Barve, Minal
    Velastegui, Karen
    Yan, Xiaohong
    Shetty, Aditya
    Der-Torossian, Hirak
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4097 - +
  • [3] KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naive, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
    Garassino, M. C.
    Theelen, W. S. M. E.
    Jotte, R.
    Laskin, J.
    De Marinis, F.
    Aguado, C.
    Badin, F. B.
    Chmielewska, I.
    Hochmair, M. J.
    Lu, S.
    Nadal, E.
    Ostoros, G.
    Felip, E.
    Spira, A. I.
    Lane, C. M.
    He, J.
    Chao, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1309 - S1310
  • [4] Advances in the treatment of KRASG12C mutant non-small cell lung cancer
    Shaverdashvili, Khvaramze
    Burns, Timothy F.
    CANCER, 2025, 131
  • [5] Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC)
    Kim, Eejung
    Tong, Xinyuan
    Patel, Ayushi
    Liu, Shengwu
    Dilly, Julien
    Hover, Laura
    Mukhopadhyay, Suman
    Sherman, Fiona
    Christensen, James G.
    Olson, Peter
    Aguirre, Andrew
    Wong, Kwok
    Ji, Hongbin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Cardona, Andres Felipe
    Recondo, Gonzalo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
    Ganguly, Arghya
    Yoo, Euna
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (06) : 536 - 537
  • [8] KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
    Mok, Tony S. K.
    Yao, Wenxiu
    Duruisseaux, Michael
    Doucet, Ludovic
    Azkarate Martinez, Aitor
    Gregorc, Vanesa
    Juan-Vidal, Oscar
    Lu, Shun
    De Bondt, Charlotte
    de Marinis, Filippo
    Linardou, Helena
    Kim, Young-Chul
    Jotte, Robert M.
    Felip, Enriqueta
    Lo Russo, Giuseppe
    Reck, Martin
    Michenzie, Mary F.
    Yang, Wenjing
    Meade, Julie N.
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8509 - LBA8509
  • [9] An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations
    Strohbehn, Garth W.
    Sankar, Kamya
    Qin, Angel
    Kalemkerian, Gregory P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (14) : 1569 - 1575
  • [10] Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
    Luo, Faustine X.
    Arter, Zhaohui Liao
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 161 - 167
12345